TY  - INPR
TI  - Smoking, alcohol and cancer mortality in Eastern European men: Findings from the PrivMort retrospective cohort study
KW  - Eastern Europe
KW  -  Smoking
KW  -  alcohol consumption
KW  -  cancer
KW  -  mortality rate
UR  - https://doi.org/10.1002/ijc.31406
Y1  - 2018/03/26/
A1  - Stefler, D
A1  - Azarova, A
A1  - Irdam, D
A1  - Scheiring, G
A1  - Murphy, M
A1  - McKee, M
A1  - King, L
A1  - Bobak, M
N2  - Eastern European men have among the highest cancer mortality rates globally. Prevalence of smoking and alcohol intake in this region is also high. The aim of this study was to calculate population attributable risk fraction (PARF) of cancer deaths from smoking and alcohol in Russia, Belarus and Hungary, and to examine the contribution of these lifestyle factors to differences in male cancer mortality in the three countries. Data was collected as part of the PrivMort retrospective cohort study. Randomly selected participants living in mid-size towns in Russia, Belarus and Hungary provided information on smoking habits, alcohol consumption, vital status and cause of death (if applicable) of male relatives (fathers, siblings and partners). PARF of cancer deaths (age 35 to 79) due to smoking, alcohol consumption and both combined was estimated between 2001 and 2013. Among 72,190 men, 4,702 died of cancer. Age standardized cancer mortality rates were similar to official data in all three countries. The estimated PARF (95% CI) associated with measures of smoking, alcohol consumption, both combined, and overall smoking or drinking were 25% (19-30), 2% (0-4), 29% (19-39) 43% (32-53) in Russia, 18% (8-28), 2% (-1-6), 28% (20-35), 38% (25-50) in Belarus, and 17% (13-20), 1% (0-3), 25% (20-30) 35% (28-42) in Hungary, respectively. These results suggest that in Eastern Europe, at least one third of cancer deaths in males may have been attributable to smoking and/or alcohol consumption in recent years. Health policies targeting these lifestyle factors can have a major impact on population health. This article is protected by copyright. All rights reserved.
JF  - International Journal of Cancer
AV  - public
ID  - discovery10046224
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
SN  - 1097-0215
ER  -